← Leaderboards
Michael A Davis
Nextrast, Inc.
$3,104,248
Attributed
$3,104,248
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $843.6K · FY2017–22$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,104,248 · 2
By mechanism
R44$3,104,248 · 2
Top collaborators
No co-investigators on record.
Most similar at Nextrast, Inc.
Same institution · by research overlap
- William Guerin Bradley$1,180,974
Others in their field
Other Emerging Leaders on “Efficacy Testing”
- Yunda Huang · Fred Hutchinson Cancer Center$72,814,726
- Julie Ake · National Institute Of Allergy And Infectious Diseases$50,742,120
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn$42,989,272
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- Abraham Aizer Brody · New York University School Of Medicine$38,894,981
Research focus
Efficacy TestingImageContrast MediaEffectivenessFrequenciesGood Laboratory PracticeColorCommercializationClinical TranslationDrug DevelopmentClinical TrialsFormulationAmericanAwardAbsorptionBaseBiologicalBiomaterial CompatibilityAnimal ModelBlood VesselsAdverse EventDoseCanis FamiliarisIntraperitoneal
Grant awards (5)
Vascular CT contrast agent development$821,821
R44 · FY2022 · HL · contact PI
Vascular CT contrast agent development$843,622
R44 · FY2021 · HL · contact PI
Vascular CT contrast agent development$249,980
R44 · FY2020 · HL · contact PI
Novel Bowel Contrast Agent for Dual Energy CT$594,198
R44 · FY2018 · DK · contact PI
Novel Bowel Contrast Agent for Dual Energy CT$594,627
R44 · FY2017 · DK · contact PI